Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | PNP | P00491 | 6/20 | 0.64 |
| ▸ | BLM | P54132 | 2/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | EDNRA | P25101 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | HBB | P68871 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | HPRT1 | P00492 | 9/20 | 0.63 |
| ▸ | POLA1 | P09884 | 1/20 | 0.63 |
| ▸ | POLG | P54098 | 1/20 | 0.63 |
| ▸ | TK1 | P04183 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | VCP | P55072 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8720011 | 0.93 | TK1 (0.66) | POLBPNPBLMUSP2TSHR | |
| SCHEMBL10430808 | 0.87 | PNP (0.71) | POLBPNPBLMUSP2TSHR | |
| SCHEMBL2346358 | 0.87 | PNP (0.79) | POLBPNPBLMUSP2TSHR | |
| SCHEMBL17622611 | 0.86 | POLB (0.64) | POLBPNPBLMUSP2TSHR | |
| SCHEMBL17617332 | 0.85 | POLB (0.63) | POLBPNPBLMUSP2TSHR | |
| SCHEMBL29286376 | 0.85 | TK1 (0.76) | PNPBLMUSP2TSHREDNRA | |
| SCHEMBL12820582 | 0.84 | HPRT1 (0.67) | POLBPNPBLMUSP2TSHR | |
| SCHEMBL2734888 | 0.83 | POLB (0.73) | POLBPNPBLMUSP2TSHR | |
| SCHEMBL28753362 | 0.83 | POLB (0.61) | POLBPNPBLMUSP2TSHR | |
| Gs-438 SCHEMBL64567 | 0.83 | POLB (0.80) | POLBPNPHPRT1POLA1POLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404332-B2 | Methods for diagnosing and treating cancers | RESEARCH DEVELOPMENT FOUNDATION (US) | 2025-09-02 | — | — | US | claimed |
| US-20230110614-A1 | HEPARIN AND N-ACETYLCYSTEINE FOR THE TREATMENT OF A RESPIRATORY VIRUS | ATOSSA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | claimed |
| EP-4125936-A1 | HEPARIN AND N-ACETYLCYSTEINE FOR THE TREATMENT OF A RESPIRATORY VIRUS | Atossa Therapeutics, Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| US-20210332136-A1 | METHODS FOR DIAGNOSING AND TREATING CANCERS | RESEARCH DEVELOPMENT FOUNDATION (US) | 2021-10-28 | — | — | US | claimed |
| WO-2021194890-A1 | HEPARIN AND N-ACETYLCYSTEINE FOR THE TREATMENT OF A RESPIRATORY VIRUS | ATOSSA THERAPEUTICS, INC. (US) | 2021-09-30 | — | — | WO | claimed |
| WO-2021183973-A1 | METHODS FOR DIAGNOSING AND TREATING CANCERS | RESEARCH DEVELOPMENT FOUNDATION (US) | 2021-09-16 | — | — | WO | claimed |
| US-20160000937-A1 | MODULATION OF TELOMERE LENGTH IN TELOMERASE POSITIVE CELLS AND CANCER THERAPY | ALT SOLUTIONS, INC. | 2016-01-07 | — | — | US | claimed |
| US-20140065072-A1 | Modulation of Telomere Length in Telomerase Positive Cells and Cancer Therapy | ALT SOLUTIONS INC. (US) | 2014-03-06 | — | — | US | claimed |
| US-8580753-B2 | Modulation of telomere length in telomerase positive cells and cancer therapy | ALT SOLUTIONS INC. (US) | 2013-11-12 | — | — | US | claimed |
| US-20120107863-A1 | MODULATION OF TELOMERE LENGTH IN TELOMERASE POSITIVE CELLS AND CANCER THERAPY | ALT SOLUTIONS INC. (US) | 2012-05-03 | — | — | US | claimed |
| WO-2010028858-A1 | USE OF CIS-IMIDAZOLINES, PARTICULARLY NUTLINS, FOR TREATING CHEMO-RESISTANT CANCER DISEASES | Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) | 2010-03-18 | — | — | WO | claimed |
| EP-1532157-A4 | NOVEL PHOSPHONIC ACID BASED PRODRUGS OF PMEA AND ITS ANALOGUES | METABASIS THERAPEUTICS INC (US) | 2009-02-25 | — | — | EP | claimed |
| WO-2005090370-A1 | PHARMACOLOGICALLY ACTIVE AGENTS CONTAINING ESTERIFIED PHOSPHONATES AND METHODS FOR USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-09-29 | — | — | WO | claimed |
| US-20050192246-A1 | Pharmacologically active agents containing esterified phosphonates and methods for use thereof | US ARMY, SECRETARY OF THE ARMY | 2005-09-01 | — | — | US | claimed |
| EP-1532157-A2 | NOVEL PHOSPHONIC ACID BASED PRODRUGS OF PMEA AND ITS ANALOGUES | Metabasis Therapeutics, Inc. (US) | 2005-05-25 | — | — | EP | claimed |
| WO-2004037161-A2 | CYCLIC PRODRUGS OF PMEA ONE OF ITS ANALOGUES | METABASIS THERAPEUTICS, INC. (US) | 2004-05-06 | — | — | WO | claimed |
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | METABASIS THERAPEUTICS, INC. | 2003-12-11 | — | — | US | claimed |
| US-6093816-A | Cationic lipids | ISIS PHARMACEUTICALS, INC. (US) | 2000-07-25 | — | — | US | claimed |
| US-6060463-A | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs | Freeman, William (US) | 2000-05-09 | — | — | US | claimed |
| US-5869468-A | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs | FREEMAN WILLIAM R (US) | 1999-02-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | MTAP, PNP, MPO | POLB 84/4885PNP 2/4885BLM 1766/4885 |
| US-20050192246-A1 | Pharmacologically active agents containing esterified phosphonates and methods for use thereof | PHPT1, PPIP5K2, PHOSPHO1 | POLB 621/4885PNP 30/4885BLM 3780/4885 |
| US-12404332-B2 | Methods for diagnosing and treating cancers | CHEK1, CHEK2, MRE11 | POLB 248/4885PNP 1312/4885BLM 49/4885 |
| US-20210332136-A1 | METHODS FOR DIAGNOSING AND TREATING CANCERS | CHEK1, CHEK2, MRE11 | POLB 248/4885PNP 1312/4885BLM 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.